Taboola to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open […]
Montauk Renewables Announces Third Quarter 2024 Results
PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company […]
Carbeeza Inc. Announces Management Transition
CALGARY, Alberta, Nov. 12, 2024 (GLOBE NEWSWIRE) — Carbeeza Inc. (“Carbeeza” or the “Company“) (TSXV:AUTO) (OTCQB: CRBAF) announces a senior […]
Toll Brothers’ Website to Broadcast Its Fourth Quarter 2024 Earnings Conference Call Live on December 10, 2024 at 8:30 a.m. (ET)
FORT WASHINGTON, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, […]
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European […]
Synchronoss Technologies to Present at Upcoming Investor Conferences
BRIDGEWATER, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader […]
LGI Homes Announces Pricing of $400 Million of Unsecured Senior Notes due 2032
THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) (“LGI Homes” or the “Company”) today […]
CarGurus to Present at RBC Capital Markets 2024 Global Technology, Internet, Media and Telecommunications Conference
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) — CarGurus, Inc. (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, […]
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat […]
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are […]
